Adaptimmune has an existing cell therapy with one TCR in multiple cancer trials in the U.S., with promising interim results from a Phase I/II trial for multiple myeloma reported in December at the annual conference of the American Society of Hematology. That clinical program targets a peptide from two cancer testis antigens, NY-ESO-1 and LAGE-1, both proteins expressed in multiple cancers. The company is running studies in the U.S. in multiple myeloma, melanoma, synovial sarcoma, and ovarian cancer. The company's therapy re-engineers patients' T lymphocytes to target and kill cancer cells when re-infused into the body, by fine-tuning the ability of the T cells to recognize the small protein fragments from intracellular cancer-specific proteins presented on the cell surface.